CG
AXSM icon

Cynosure Group’s Axsome Therapeutics AXSM Stock Holding History

Cynosure Group’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$442K Sell
2,617
-858
-25% -$148K 0.06% 108
2025
Q4 		$635K Sell
3,475
-4,369
-56% -$610K 0.06% 103
2025
Q3 		$953K Hold
7,844
– – 0.1% 80
2025
Q2 		$819K Buy
7,844
+2,439
+45% +$258K 0.09% 113
2025
Q1 		$630K Sell
5,405
-1,142
-17% -$130K 0.09% 134
2024
Q4 		$554K Sell
6,547
-1,383
-17% -$127K 0.08% 131
2024
Q3 		$713K Buy
+7,930
New +$692K 0.1% 123

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cynosure Group's AXSM Position: Q1 2026 in Review

Cynosure Group reduced its Axsome Therapeutics (AXSM) stake by 25% in Q1 2026, selling an estimated $148K and leaving 2,617 shares worth $442K. The position accounts for 0.06% of the portfolio, ranked #108.

Cynosure Group first reported a position in AXSM in Q3 2024 and has held it in 7 quarters since. The position peaked at $953K in Q3 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Cynosure Group held 2,617 shares of Axsome Therapeutics worth $442K as of Q1 2026.
  • Cynosure Group sold 858 Axsome Therapeutics shares in Q1 2026, an estimated $148K.
  • Axsome Therapeutics made up 0.06% of Cynosure Group's portfolio in Q1 2026, its #108 holding.
  • Cynosure Group first reported a position in Axsome Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Cynosure Group's Axsome Therapeutics position peaked at $953K in Q3 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Cynosure Group's 13F filing for Q1 2026, filed 14 May 2026.